Loading...
•
Dec 30, 2024
Lyra Q4 2024 Earnings Report
Lyra Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting a decrease in net loss and operating expenses for the quarter, while also providing updates on its clinical trials and a planned reverse stock split.
Key Takeaways
Lyra Therapeutics reported a net loss of $11.0 million for the fourth quarter of 2024, an improvement from $15.1 million in the same period last year. The company's total operating expenses decreased to $97.882 million from $68.678 million in the prior year, primarily due to reduced clinical and employee-related costs. Cash and cash equivalents stood at $40.6 million, sufficient to fund operations into Q1 2026.
Net loss for Q4 2024 was $11.0 million, a decrease from $15.1 million in Q4 2023.
Total operating expenses for Q4 2024 were $97.882 million, an increase from $68.678 million in Q4 2023.
Cash and cash equivalents as of December 31, 2024, were $40.6 million, expected to fund operations into Q1 2026.
Topline results from the ENLIGHTEN 2 pivotal Phase 3 clinical trial of LYR-210 are expected in Q2 2025.
Lyra
Lyra
Lyra Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Lyra Therapeutics anticipates topline results from the ENLIGHTEN 2 pivotal Phase 3 clinical trial of LYR-210 in Q2 2025. The company also plans to implement a reverse stock split to maintain its Nasdaq listing, pending stockholder approval in Q2 2025.
Positive Outlook
- Upcoming readout from ENLIGHTEN 2 Phase 3 study in Q2 2025 expected to provide important data on LYR-210 efficacy.
- Continued analysis of positive post-hoc data from ENLIGHTEN 1 Extension Study in polyp cohort, consistent with previous results.
- Engagement with FDA to align on details for a registration path in CRS with polyps.
- Anticipated additional ~30 polyp patients in ENLIGHTEN 2 trial, increasing total polyp patients in ENLIGHTEN program to ~65.
- Cash and cash equivalents are sufficient to fund operating expenses and capital expenditures into Q1 2026.
Challenges Ahead
- The company's ability to continue as a going concern is a risk.
- The company has no approved products yet.
- Clinical trial data is subject to change until completion of the applicable clinical study report.
- Clinical trials are expensive, time-consuming, and their outcome is uncertain.
- The company's common stock price may be volatile and fluctuate substantially.